Wall Street In and Out of Love with NASH Drug Developers
ACCESSWIRE - Tue May 13, 9:21AM CDT
WHITEFISH, MT / ACCESSWIRE / May 13, 2014 / When Intercept Pharmaceuticals (NASDAQ: ICPT) announced early in January that its mid-stage FLINT trial of obethicholic acid (OCA) for non-alcoholic steatohepatitis (NASH) was stopped early because it had already hit its primary endpoint, the stock went parabolic, shooting from $72 to a high of $497 in less than two days. That's a move of 590 percent for those keeping track. After a pullback and another run near that high, the stock has been halved to around $240 per share.
Galectin Therapeutic Down 20.3% Since SmarTrend Downtrend Call (GALT)
Comtex SmarTrend(R) - Mon May 12, 12:21PM CDT
SmarTrend identified a Downtrend for Galectin Therapeutic (NASDAQ:GALT) on April 4th, 2014 at $12.86. In approximately 1 month, Galectin Therapeutic has returned 20.26% as of today's recent price of $10.25.
Galectin Therapeutics to Hold Conference Call to Provide Corporate Update Following Company's Annual Meeting of Shareholders
GlobeNewswire - Thu May 08, 7:00AM CDT
Galectin Therapeutics (Nasdaq:GALT) will host a conference call at 9:45 A.M. Eastern Time on Wednesday, May 14, 2014, to provide a corporate update following the Company's Annual Meeting of Shareholders. Additionally, Peter Traber, MD, President, CEO and CMO of Galectin Therapeutics, will update the investment community on the Company's pipeline of galectin inhibitor compounds and progress in development of treatments for liver fibrosis and cancer.
Diabetic Nephropathy - Pipeline Review, H1 2014: 37 Companies and 58 Drugs Profiled
M2 - Thu May 08, 3:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x6n63h/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Nephropathy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diabetic Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved: - AbbVie Inc. - Ampio Pharmaceuticals, Inc. - Angelini Group - Astellas Pharma Inc. - Bayer AG - CCRP Therapeutics GmbH - ChemoCentryx, Inc. - Chong Kun Dang Pharmaceutical Corp. - Concert Pharmaceuticals, Inc. - Cyano Biotech GmbH - Daiichi Sankyo Company, Limited - Dongwha Pharm Co., Ltd. - Eli Lilly and Company - Emergent BioSolutions Inc. - Fibrotech Therapeutics Pty. Ltd. - GNI Group Ltd. - Galectin Therapeutics - GenKyoTex S.A. - Gentium S.p.A. - Glucox Biotech AB - IMMD Inc. - Intercept Pharmaceuticals, Inc. - Inventiva SAS - Johnson & Johnson - Mesoblast Limited - Mitsubishi Pharmaceutical Corporation - Mitsubishi Tanabe Pharma Corporation - NephroGenex, Inc. - Noxxon Pharma AG Drug Profiles: - canagliflozin - atrasentan hydrochloride - baricitinib - NOX-E-36 - IMD-1041 - CS-3150 - DW-1029M - GKT-137831 - PF-00489791 - CCX-140 - LY-2382770 - bindarit - Colchicine - probucol - PF-04634817 - Pyridoxamine Dihydrochloride - GLY-230 - corticotropin - CTP-499 - MT-3995 - finerenone - cilostazol - PHN-033 - CKD-322 - Allogeneic Mesenchymal Precursor Cells For Diabetic Nephropathy - LY-3016859 - FT-011 - ASP-8232 - pirfenidone - THR-123 For more information visit http://www.researchandmarkets.com/research/x6n63h/diabetic
Kidney Fibrosis - Pipeline Review, H1 2014: 15 Company and 18 Drug Profiles
M2 - Wed May 07, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6wq329/kidney_fibrosis) has announced the addition of the "Kidney Fibrosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Fibrosis and special features on late-stage and discontinued projects. This report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - AbbVie Inc. - Angion Biomedica Corp. - BiOrion Technologies B.V. - BioLineRx, Ltd. - CisThera Inc. - Compugen Ltd. - GNI Group Ltd. - Galectin Therapeutics - Galecto Biotech AB - Genzyme Corporation - Intercept Pharmaceuticals, Inc. - Paloma Pharmaceuticals, Inc. - ProMetic Life Sciences Inc. - Raptor Pharmaceuticals Corp. - Regulus Therapeutics Inc. Drug Profiles: - paricalcitol - F-351 - CGEN-856 - CGEN-857 - cysteamine DR - INT-767 - PBI-4050 - GR-MD-02 - Anti microRNA-21 - Galectin-3 Inhibitors - 1D-11 - CT-140 - BOT-191 - BOT-190 - SOL-1 - LJ-1888 - P-529 - ANG-3298 For more information visit http://www.researchandmarkets.com/research/6w...y_fibrosis
15.0% Return Seen to Date on SmarTrend Galectin Therapeutic Call (GALT)
Comtex SmarTrend(R) - Mon May 05, 9:51AM CDT
SmarTrend identified a Downtrend for Galectin Therapeutic (NASDAQ:GALT) on April 4th, 2014 at $12.86. In approximately 1 month, Galectin Therapeutic has returned 15.01% as of today's recent price of $10.93.
Galectin Therapeutic Down 12.9% Since SmarTrend Downtrend Call (GALT)
Comtex SmarTrend(R) - Mon Apr 28, 9:14AM CDT
SmarTrend identified a Downtrend for Galectin Therapeutic (NASDAQ:GALT) on April 4th, 2014 at $12.86. In approximately 3 weeks, Galectin Therapeutic has returned 12.87% as of today's recent price of $11.20.
Galectin Therapeutics Completes Enrollment of Second Cohort of Phase 1 Trial of GR-MD-02 for NASH (Fatty Liver Disease) With Advanced Fibrosis
GlobeNewswire - Wed Apr 23, 7:00AM CDT
Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that all eight (
Galectin Therapeutics Rises on GR-MD-02 Update - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 21, 3:45PM CDT
Share price of Galectin Therapeutics jumped 12.9% after the company announced dosing of the first patient in cohort 2 of a phase I study on GR-MD-02.
Galectin Therapeutics doses first patient in second cohort under Phase 1 trial of GR-MD-02
M2 - Fri Apr 18, 7:15AM CDT
Therapeutics company Galectin Therapeutics (NasdaqCM:GALT) said on Thursday that it has dosed its first patient in cohort 2 of its Phase 1 clinical trial of GR-MD-02 in patients with NASH with advanced fibrosis.
Nasdaq stocks posting largest percentage increases
AP - Thu Apr 17, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Why Galectin Therapeutics Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Thu Apr 17, 3:15PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Galectin Thersapeutics , a clinical-stage...
Galectin Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1 Trial of GR-MD-02 for NASH With Advanced Fibrosis
GlobeNewswire - Thu Apr 17, 9:19AM CDT
Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that the first patient in cohort 2 of its Phase 1 clinical trial of GR-MD-02 in patients with NASH with advanced fibrosis has been successfully dosed with 4 mg/kg, which is double the dose given in cohort 1. Cohort 2, as with all phases of the clinical trial, was initiated in full compliance with the rules, regulations, and specific conditions set forth by the U.S. Food and Drug Administration (FDA) for this Phase 1 clinical trial. The second cohort follows highly successful results from the first cohort showing that 2 mg/kg was safe and very well tolerated, and that GR-MD-02 treatment resulted in significant improvement in multiple biomarkers of fibrosis and liver inflammation in patients with NASH with advanced fibrosis (see full results: http://galectintherapeutics.com/wp-content/up...FINAL.pdf). The remaining patients in cohort 2 are expected to be enrolled over the next few weeks and we anticipate reporting the results of cohort 2 around the end of July.
Recent Acquisitions, Trial Opinions, Upcoming Earnings, Inducement Grants, and Clinical Trial Results - Analyst Notes on Actavis, The Medicines Company, Hospira, Horizon Pharma, and Galectin
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), The Medicines Company (NASDAQ: MDCO), Hospira, Inc. (NYSE: HSP), Horizon Pharma, Inc. (NASDAQ: HZNP), and Galectin Therapeutics Inc. (NASDAQ: GALT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Treatments for Non-Alcoholic Steatohepatitis Making Clinical Strides
ACCESSWIRE - Tue Apr 08, 10:00AM CDT
WHITEFISH, MT / April 8, 2014 / There has been a disease steadily filling market headlines recently, and no; it's not cancer. It's fatty liver disease, particularly Non-alcoholic Fatty Liver Disease, or NAFLD, regarded by many as the most common non-communicable liver disease worldwide. The disease is a silent killer that often goes undetected until late stages, for which there are no FDA-approved treatments. Biotechs focusing on innovative therapies for varying stages of NAFLD are receiving plenty of deserved media coverage. Hepatology leaders in recent headlines include Intercept Pharmaceuticals, (NASDAQ: ICPT), Cempra, Inc. (NASDAQ: CEMP), MediciNova, Inc. (NASDAQ: MNOV), Galectin Therapeutics (NASDAQ: GALT) and Lumena Pharmaceuticals, a company preparing to go public.
Galectin Therapeutics (GALT) Falls: Stock Goes Down 11.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 02, 7:38AM CDT
Galectin has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
First Cohort Results in Galectin Therapeutics' Phase 1 Trial Reveal Biomarker Evidence of Therapeutic Effect on Fibrosis and Inflammation in NASH With Advanced Fibrosis
GlobeNewswire - Mon Mar 31, 3:37PM CDT
-- GR-MD-02 was safe and well tolerated in patients